Pacira Pharm Inc (PCRX) 37.76 $PCRX New Research: Opioid

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pacira Pharm Inc (PCRX) 37.76 $PCRX

New Research: Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known
GlobeNewswire - Mon Aug 01, 6:30AM CDT
Vast Majority of Surgeons Feel Pressure to Prescribe More Opioids than Patients Need
PCRX: 37.76 (+0.18)

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.94 (unch), CPRX: 0.74 (-0.02), AKRX: 32.81 (-0.99), PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2016 Healthcare Conference at 9 a.m. ET on Tuesday, June 7, 2016, in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Tue May 03, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQCRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company.
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained
Sean Williams, The Motley Fool - Motley Fool - Mon May 02, 3:02PM CDT
Image source: NIH Image Gallery via Flickr. What:  Shares of Pacira Pharmaceuticals , a specialty pharmaceutical company primarily focused on the development of medicines to help in the acute hospital care setting, dipped by as much as 10%...
PCRX: 37.76 (+0.18)

Pacira reports 1Q loss
Automated Insights - Mon May 02, 6:40AM CDT
PARSIPPANY, N.J. (AP) _ Pacira Pharmaceuticals Inc. (PCRX) on Monday reported a first-quarter loss of $3.9 million, after reporting a profit in the same period a year earlier.
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 6:34AM CDT
-- Total Net Revenues Up 12 Percent Year-Over-Year --
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals Appoints Charles A. Reinhart, III, as Chief Financial Officer
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQCRX) today announced the appointment of Charles A. Reinhart, III, to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently President, and will report to Dave Stack, Chief Executive Officer and Chairman. Mr. Reinhart will start in this new role effective Tuesday, May 3, 2016.
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals (PCRX) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 7:48AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) has moved higher as of late, but there could definitely be trouble on the horizon for this company
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
GlobeNewswire - Thu Apr 14, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQCRX) today announced that financial results for the company's first quarter ended March 31, 2016 will be released before the market opens on Monday, May 2, 2016. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Monday, May 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 54803652.
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQCRX) today announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr. Weiland will be responsible for oversight of the commercial activities for EXPAREL (bupivacaine liposome injectable suspension), which include marketing, sales, national accounts, training and commercial operations and analytics. Mr. Weiland will report to Jim Scibetta, President and Chief Financial Officer.
PCRX: 37.76 (+0.18)

Pacira (PCRX): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 9:05AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
PCRX: 37.76 (+0.18)

PixarBio's NeuroRelease(TM) A Revolutionary Non Addictive Pain Treatment Draws Pain Industry Star Sales Executive David Kaplan as Global VP of Sales & Marketing
BusinessWire - Wed Mar 09, 5:00AM CST
PixarBio Corporation inventors of NeuroRelease, a 14 day non-addictive post-surgical pain treatment with expected FDA approval in 2018, announced today the appointment of David Kaplan as Vice President of Global Sales and Marketing.
PCRX: 37.76 (+0.18)

Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 6:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company.
PCRX: 37.76 (+0.18)

CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 3:04PM CST
CTI BioPharma Corp. (CTIC) announced that the FDA has placed the company's Investigational New Drug (IND) application for pacritinib on a full clinical hold.
GILD: 80.90 (+0.44), MYL: 46.00 (-0.74), CTIC: 0.33 (-0.01), PCRX: 37.76 (+0.18)

Catalyst (CPRX) Initiates Study on Firdapse for MuSK-MG
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:25PM CST
Catalyst Pharmaceuticals, Inc. (CPRX) announced the initiation of a well-controlled study evaluating the efficacy, safety and tolerability of Firdapse for the treatment of MuSK-MG.
EARS: 4.17 (+0.03), CPRX: 0.74 (-0.02), CORT: 5.76 (-0.01), PCRX: 37.76 (+0.18)

Shire's NDA Resubmission for Lifitegrast Accepted by FDA
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 3:15PM CST
Shire plc (SHPG) announced that the FDA has acknowledged the receipt of the company's New Drug Application (NDA) for its pipeline candidate, lifitegrast.
AGN: 253.07 (-1.79), SHPG: 202.27 (+8.27), CORT: 5.76 (-0.01), PCRX: 37.76 (+0.18)

Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.35 (+0.06), CORT: 5.76 (-0.01), PCRX: 37.76 (+0.18), BIOD: 0.40 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 60

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 19

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 24

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 139

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 11

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 94

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 31

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

BitGo Faces Securities Fraud Suit Amid Investor Losses

Updated Category News Views 69

BitGo's Legal Woes: A Deep Dive into the Allegations A lawsuit can shake up a company's foundations, and BitGo Holdings, Inc. (NYSE: BTGO) is feeling the heat right now. The focus of this busy investor morning isn’t some penny stock drama; we're talking about players in the digital asset game accused of pulling the wool over investors' eyes. Slap on those reading...

Continue Reading
Investors Alert: Deadline Approaches in Match Group Lawsuit

Updated Category News Views 141

Important Deadline Approaching for Match Group Investors Recently, there has been a notable reminder for investors concerning a class action lawsuit involving Match Group, Inc. (NASDAQ: MTCH). The law firm Glancy Prongay & Murray LLP has highlighted that all individuals who purchased shares in Match Group during the specified period should be aware of the upcoming...

Continue Reading
Leadership Transition at Coloplast A/S: New Era Begins

Updated Category News Views 937

Coloplast A/S Announces Leadership Change In a significant shift for Coloplast A/S, CEO Kristian Villumsen has officially stepped down. Today marks the start of a new chapter as the Board of Directors mobilizes Lars Rasmussen to serve as interim CEO while the search for a permanent replacement is conducted. Strategic Shift for the Future This change comes at an opportune...

Continue Reading
Johnson & Johnson's Strong Q3 Results Amid Market Declines

Updated Category News Views 109

Market Overview On a day marked by declining values, U.S. stocks experienced a noticeable downturn. The Nasdaq Composite index saw a drop of around 150 points, indicating a challenging market environment. As trading progressed, the Dow Jones Industrial Average slipped slightly, and the S&P 500 also followed suit, showing varied performance across sectors. Sector...

Continue Reading
Moroccanoil Expands Product Line at Ulta Beauty Nationwide

Updated Category News Views 204

Moroccanoil Expands Product Line at Ulta Beauty Nationwide Moroccanoil is thrilled to announce an exciting partnership with Ulta Beauty, the premier beauty retailer in the nation. This significant expansion reaffirms Moroccanoil's commitment to delivering high-quality beauty products to a wider audience while honoring its legacy rooted in the salon community. Launching at...

Continue Reading